News

CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant. Titled “Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring,” the grant will provide $952,558 in research funding to develop new features that will be embodied in the Company’s next generation CytoR2 Platform for advanced cell sorting.

The research will be conducted in the laboratories of Dr. Rafael Davalos, Virginia Tech’s L. Preston Wade Professor of Biomedical Engineering, Dr. Nathan Swami, UVA Professor of Electrical and Computer Engineering, and the CytoRecovery laboratory located at the Virginia Tech Corporate Research Center (VT CRC) in Blacksburg, VA, under the direction of Dr, Alex Hyler, who is the Principal Investigator (PI) for the NSF grant.

“We are pleased to receive this prestigious SBIR research grant from the NSF and for the validation of our technology that it represents,” stated Dr. Hyler. She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. To address this challenge, we have brought to market our CytoR1 Platform – a label-free, fully-integrated product system for cell sorting, enrichment, and recovery.”

The funding will be used to advance features, progress software, and develop new technologies for marker free cell sorting, including integrating the processes of cell sample preparation and expanding capabilities to monitor cells in the Company’s proprietary, microfluidic chips.

Learn more here.

Recent News

06/12/2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential

06/11/2024

KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury

05/31/2024

Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst